Genocea Preclinical Data at SITC Demonstrate that Inhibitory Neoantigens in an Otherwise Protective Vaccine Reverse Anti-Tumor Responses
ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination
Inhibitory T cell responses exacerbate tumor growth
In the preclinical studies, when an ATLAS-identified stimulatory neoantigen was combined in a vaccine formulation and therapeutically administered as monotherapy into tumor-bearing mice, tumor growth was either significantly delayed or completely abrogated. This effect was durable and protected animals from tumor re-challenge. Conversely, when an ATLAS-identified inhibitory neoantigen was combined in the same vaccine, tumor growth was comparable to unvaccinated controls; i.e. vaccinating with an inhibitory neoantigen completely reversed protective anti-tumor responses. These data corroborate ATLAS-based clinical data presented yesterday (P417) showing that the ratio of inhibitory to stimulatory T cell responses to neoantigens strongly correlates with patient responses to immunotherapy.
Specifically targeting of stimulatory neoantigens while avoiding inhibitory antigens is a cornerstone of GEN-009 personalized immunotherapy, based on interim results presented in two separate posters yesterday (P417) and today (P420). In Part A of the GEN-009-101 Phase 1/2a trial, all subjects mounted T cell responses to vaccination, and responses were seen to 99% of vaccine antigens. To date, no subjects have had identified recurrences.
“These results point to the true power and utility of ATLAS,” said
“The combination of the murine data and the immunogenicity results from the GEN-009 clinical trial suggest that ATLAS, which selects patient-specific targets for vaccine inclusion, results in a broadly immunogenic therapy,” stated
Posters P420 and P678 are located in Prince George's
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. To learn more, please visit www.genocea.com.
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended
Source: Genocea Biosciences, Inc.